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The cholesterol-lowering drug ﬂuvastatin (FS) has an inhibitory eﬀect on the growth of the pathogenic yeast Candida albicans
that is dependent on the pH of the medium. At the low pH value of the vagina, FS is growth inhibitory at low and at high
concentrations, while at intermediate concentrations (1–10mM), it has no inhibitory eﬀect. Examination of the eﬀect of the
common antifungal drug ﬂuconazole in combination with FS demonstrates drug interactions in the low concentration range.
Determination of intracellular stress and the activity of the FS target enzyme HMG-CoA reductase conﬁrm our hypothesis that in
the intermediate dose range adjustments to the sterol biosynthesis pathway can compensate for the action of FS. We conclude that
thepHdependentuptakeofFSacrossyeastmembranesmightmakeFScombinationtherapyanattractivepossibilityfortreatment
of vaginal C. albicans infections.
Copyright © 2009 Martin Schmidt et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Fluvastatin (FS) is a widely prescribed inhibitor of HMG-
CoA reductase, the key enzyme in sterol biosynthesis [1].
Inhibition of sterol synthesis by ﬂuvastatin has an antifungal
eﬀect on the opportunistic yeast pathogen Candida albicans
and at high concentrations; the antifungal action of FS is
synergistic with the action of other antifungal drugs [2, 3].
However, a combination drug therapy against C. albicans in
which FS is combined with the commonly prescribed azole
drugs seems impractical due to the high concentrations of FS
required for an inhibitory eﬀect at physiological pH [2, 3].
FS stands out from the other members of the statin
family in that it is a fully synthetic molecule with a terminal
carboxylic acid group. Because of its pKa of 5.5, FS is
ionized at the physiological pH of 7.4. FS uptake into cells
is dependent on pH. The uncharged protonated form of FS
in the acidic pH of the intestine is taken up more readily that
the charged molecule is present at serum pH [4].
The present study was undertaken to show that FS action
on yeast is similarly dependent on the pH of the medium. It
is of particular interest to establish if a more eﬀective uptake
of FS at low pH leads to synergism of FS with azole drugs at
lower readily achievable statin concentrations.
2.MaterialsandMethods
2.1. Assessing Yeast Growth. C. albicans strains from our
collection of clinical isolates [5] were grown in synthetic
medium [6] pH-adjusted with 0.1M Sodium Phosphate
buﬀer. Yeast growth was assayed by a modiﬁed microtiter
broth dilution method [6]. Stationary cultures of yeast were
diluted 1/20 000 in fresh medium, aliquoted to 200μL
with the indicated concentrations of drugs and incubated
for 40 hours at 37
◦C in 96-well microtiter plates. Growth
was estimated by recording the optical density at 620nm
(OD620) with a microplate reader. Minimal inhibitory
concentrations (MICs) of drugs were determined as doses
that reduced OD620 by >50% compared to control [7].
2.2. Assessing CDR1 Expression. The expression of the stress-
response gene CDR1 was monitored by recording the
ﬂuorescence of C. albicans r e p o r t e rs t r a i nC a S A 1i nw h i c h
the expression of green-ﬂuorescent protein is under control
of the CDR1 promoter [8].
2.3. Determination of HMG-CoA Reductase Activity. Ten
OD600 units of a culture of C. albicans strain ATCC10231
in synthetic medium were harvested in mid log phase of2 Research Letters in Biochemistry
growth, washed twice with water and suspended in 300μL
of 100mMKPO4 buﬀer at pH7.0 supplemented with yeast
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, Mo,
USA). After addition of 300μL of acid-washed glass beads,
cells were ruptured in a Beadbeater instrument (Biospec,
Bartlesville, Okla, USA). After removing cell debris from the
glass-bead supernatant, HMG-CoA reductase activity in the
crude extract was determined by following the oxidation
of NADPH at 340nm. The assay contained 0.3mM HMG-
CoA, 0.2mM NADPH, 40mM Dithiothreitol, and 10μLo f
crude lysate in 100mM KPO4 buﬀer at pH7.0. Activity was
normalized to protein concentration in the extract. Averages
and standard deviations of 3 independent experiments were
calculated [9].
2.4. Quantitative PCR. Expression of UPC2 [10] was assayed
by quantitative reverse transcriptase PCR (qPCR). Total
RNA was isolated with the Yeast Master Pure RNA kit
(Epicentre Biotechnology, Madison, Wis) according to the
manufacturer’s instructions. qPCR was carried out using
the qTaq DNA polymerase kit (Clontech, Mountain View,
Calif) at a template concentration of 50ng/μL. The following
primers were used: PMA1 (control 1) 5  TCCAACCTTTC-
GATCCTGTC 3  and 5  TTCCCAGTGACCTTCACCTC
3 ;1 6 SR N A( c o n t r o l2 )5  ATGGCCGTTCTTAGTTGGTG
3  and 5 GCCAAGGGTTATACTCGCTG 3 ;U P C 25  
CAGCACTTTTGGACAAGCAA 3  and GCTCCACCTGCG-
TACTCTTC 3 . Averages and standard errors for three
independent experiments are given.
3. Results andDiscussion
3.1. Inhibition of C. albicans Growth by FS Is Dependent
on Environmental pH. The eﬀect of FS on growth of C.
albicans was examined in four diﬀerent clinical isolates from
our collection. A typical dose-response curve is shown in
Figure 1(a). While at a pH of 7.0FS, it exhibits a simple
dose/responsecorrelation,thesituationatpH4.5isdiﬀerent.
Growth inhibition can be observed at low (0.5–1.0μM) and
high (>10μM) concentrations, but not in the intermediate
concentrationrangeof1–10μM.Ofthe6statinsexaminedin
this study (Atorvastatin, Fluvastatin, Lovastatin, Mevastatin,
Pravastatin, Simvastatin), FS was the only drug exhibiting a
nonlinear dose response.
The low-dose growth-inhibitory action of FS at low
pH values can be understood in light of the previously
demonstrated pH dependency of FS uptake across biological
membranes [4]. We propose that the protonated uncharged
FS molecule has better access to the yeast cytoplasm than
the charged molecule and thus can inhibit growth at lower
concentrations.
The morphology of statin-treated cells was examined by
light microscopy. There was no change in cell shape or size
upon exposure to FS (data not shown).
The low dose/low pH inhibitory eﬀect of FS can be
exploited to sensitize C. albicans to the action of a common
antifungal drug, ﬂuconazole (Figure 1(b)). An azole drug
was chosen for the analysis because both azoles and statins

















































Figure 1: Impact of Fluvastatin (FS) on survival and Fluconazole
resistance of C. albicans. (a) Growth inhibition of clinical isolate
275G by FS. Squares, pH 4.5; Triangles, pH 7. Relative growth is
given as OD620 treated/ OD620 untreated culture at the respective
pH (4.5 or 7.0). At pH 4.5, FS causes growth inhibition at low
concentrations. (b) FS, at low concentration/low pH, enhances the
growthinhibitionbyﬂuconazole.Squares:strain275GgrownatpH
4.5 without FZ; triangles: same strain grown with 0.2μMF S .
inhibit the synthesis of the major fungal membrane lipid
ergosterol. While the statins inhibit an early step, the
reduction of the steroid precursor hydroxymethylglutaryl-
CoA (HMG-CoA), azoles inhibit a later enzymatic step, the
demethylation of 14α-lanosterol [11].
The ﬂuconazole sensitivity of eight clinical isolates of C.
albicans was assayed in the presence and absence of 0.5mM
FS. In all strains tested, the addition of FS lowered the MIC
f o rﬂ u c o n a z o l eb ya tl e a s taf a c t o ro ff o u r .
In order to validate the observed FS-mediated increases
and decreases in ﬂuconazole resistance, a checkerboard
analysis [3] was performed at pH 4.5. However the low-dose
sensitizing eﬀects of FS did not meet the stringent criteria for
synergism as put forward by White and coworkers [12].
3.2. CDR1-Fluorescence and HMG-CoA Activity Mirror FS
Action. In an eﬀort to better understand the biological
implications of the nonlinear FS dose-response curve shown
in Figure 1(a), we assessed the intracellular stress levels and
HMG-CoA reductase activities of FS-treated C. albicans.T h e
expression of the drug exporting pump Cdr1p increases after
exposure to a variety of stress factors and is considered a
useful reporter for intracellular stress [8]. The FS-induced
changes in CDR1 gene expression are a mirror image of
the drug’s growth inhibitory eﬀect (Figure 2(a)). In the
intermediate concentration range of 1–10μM, FS does notResearch Letters in Biochemistry 3






















































activity in C. albicans. (a) Fluorescence and growth of CDR1
reporter strain CaSA1 in the presence of FS. Squares: Growth
of CaSA1 relative to growth of FS-untreated cells. Triangles:
Corresponding GFP ﬂuorescence of samples. The intensity of GFP
ﬂuorescence is a measure of CDR1 expression and thus reﬂects the
strength of the stress response. In the intermediate concentration
range of 1–10μM that does not inhibit growth the cells do not
exhibit signs of stress. (b) HMG-CoA reductase activity of strain
ATCC10231 in arbitrary units. In the intermediate concentration
range, HMG-CoA reductase is not as strongly inhibited as in the
low range.
induce drug resistance mechanisms. A similar correlation
can be observed in the FS-induced changes in HMG-CoA
reductase activity. While a low dose of FS inhibits C. albi-
cans HMG-CoA reductase, the intermediate dose inhibits
the enzyme signiﬁcantly less (Figure 2(b)). Induction of the
major steroid synthesis regulator UPC2[10], as determined
by qPCR, is detectable at low FS concentrations (factor 1.53
+/− 0.28 at 0.5μM), indicating that FS indeed has a physi-
ological eﬀect in this range. However, UPC2 induction does
not increase signiﬁcantly with escalating FS concentrations
(factor 1.69 +/− 0.24 at 20μM) and can thus not explain an
adaptive response at intermediate concentrations.
We propose the following explanation for our observa-
tions At a low pH, the uncharged FS molecules enter the
cell by diﬀusion though the membrane. Inside the cell, FS
gets trapped by deprotonation at the higher intracellular pH,
leading to an intracellular accumulation with subsequent
inhibition of ergosterol biosynthesis. If a certain level of
inhibitionisexceeded,thecellmightrespondbyinducingthe
activity of the steroid synthesis pathway [10, 13], apparently
by a UPC2-independent mechanism. This then would lead
to adequate production of ergosterol and to a lowering of
intracellular stress in the presence of FS. Clearly, further
studies are required to fully explain the FS resistance in the
intermediate concentration range.
4. Conclusions
The data about the pH dependency of FS action on C.
albicans give insight into the impact of statin therapy on
yeast infection. In patients taking FS for the treatment of
hypercholesterolemia, the serum concentration of FS falls
into the intermediate range of 2–4μM[ 14]. No fungistatic
or fungicidal action of FS can be expected in this range,
as the eﬀective concentration of FS at physiological pH is
>12.5μM. However, at the low pH of the vagina (pH 3.8
to 4.5) low doses of FS are suﬃcient to reduce C. albicans
survival. It is an appealing hypothesis that FS can used alone
or in combination with azoles to improve fungal clearance
from the vagina.
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